Xilio Therapeutics (XLO) Invested Capital (2020 - 2023)

Xilio Therapeutics has disclosed Invested Capital across 4 years of filings, most recently posting $40.1 million for Q4 2023.

• In Q4 2023, Invested Capital fell 65.24% year-over-year to $40.1 million; the TTM figure through Dec 2023 stood at $40.1 million (down 65.24% YoY), while the FY2023 annual figure was $40.1 million, down 65.24% from the prior year.
• Invested Capital came in at $40.1 million for Q4 2023 at Xilio Therapeutics, down from $57.5 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $195.1 million in Q4 2021 to a low of -$126.9 million in Q3 2021.
• Average Invested Capital over 4 years is $76.5 million, with a median of $93.0 million recorded in 2023.
• Year-over-year, Invested Capital soared 365.23% in 2021 and slumped 65.24% in 2023.
• Over 4 years, Invested Capital stood at -$73.5 million in 2020, then soared by 365.23% to $195.1 million in 2021, then plunged by 40.8% to $115.5 million in 2022, then plunged by 65.24% to $40.1 million in 2023.
• Per Business Quant data, the three most recent Invested Capital figures were $40.1 million in Q4 2023, $57.5 million in Q3 2023, and $74.5 million in Q2 2023.